JAMA Netw Open:远程医疗的未来在哪里?

2021-01-15 MedSci原创 MedSci原创

到目前为止,保健专业人员对远程保健在癌症护理方面的效用的看法还没有很好地了解。

远程医疗是一种新兴的护理提供模式,它可以改善患者获得护理的机会,降低成本,提高患者和健康专业经验,同时提供有效的护理。远程医疗的一个核心组成部分是视频就诊,其中,视听技术用于连接患者和卫生专业人员,而不是面对面接触。视频访问允许医生评估患者并提供治疗建议,而不考虑地理距离。虽然医生在视频访问期间进行身体检查的能力有些有限,但许多检查技术仍然可行,远程医疗和传统的面对面访问具有类似的表现特征。

一项随机对照试验指出,在根治性前列腺切除术后进行视频与亲自就诊随访,显示了同等的效率、相似的满意度和显著降低的成本。此外,多项研究表明,远程保健可以改善农村地区的患者获得癌症护理的机会,同时与亲自探访相比,还能使患者获得同等或更好的满意度,并节省成本。

尽管远程医疗有许多优势,但在肿瘤学中的应用是高度多变的,而且在全国范围内,远程医疗的应用有限(直到最近由于2019冠状病毒病大流行而激增)。到目前为止,保健专业人员对远程保健在癌症护理方面的效用的看法还没有很好地了解。

近日,JAMA Network Open上发表了一项新得研究就探索了肿瘤科卫生专业人员对COVID-19大流行之前患者护理使用远程医疗的看法。

该定性研究使用了从2019年10月30日至2020年3月5日对托马斯·杰斐逊大学医院(Thomas Jefferson University Hospital)肿瘤学专业人员进行的访谈。托马斯·杰斐逊大学医院是美国一个设有癌症中心的城市学术卫生系统。医院所有肿瘤内科医生、医师助理和执业护士均有资格参加。最终有29名肿瘤医疗专业人员(包括20名医生和9名高级执业专业人员)参与了半结构化访谈。

研究的主要结果为肿瘤科医疗专业人员对接受癌症治疗的患者远程医疗视频访问的障碍和好处的看法。

29名参与者中,15名(52%)为女性,22名(76%)为白人,平均年龄为48.5岁(12.0岁)。受访者的看法是利用国家质量论坛框架的4个领域:临床效果、患者体验、获得护理的机会和财务影响来组织的。受访者不同意虚拟体检的临床效果和潜在局限性,以及对患者的经济影响。受访者也基本上认识到远程医疗为患者提供了方便和更好的医疗服务。然而,许多报告担心卫生专业人员与病人的关系,以及他们在虚拟环境中安慰病人的能力有限。

医疗专业人员对临床有效性的看法

医疗专业人员对患者经验的看法

医疗专业人员对获得保健的看法

医疗专业人士对财务影响或成本的看法

总体来说,对于远程医疗在临床效果、患者体验、医疗服务的获取和经济影响方面的障碍和好处,肿瘤科医疗专业人员有着相互矛盾的看法。了解肿瘤学家对远程保健的看法,阐明了需要进一步研究或改进的潜在障碍,以扩大和继续利用远程保健;考虑到COVID-19大流行期间远程医疗的迅速扩展,目前正在进行进一步的研究,以评估卫生专业人员和患者当前的看法。

参考文献:Heyer A, Granberg RE, Rising KL, Binder AF, Gentsch AT, Handley NR. Medical Oncology Professionals’ Perceptions of Telehealth Video Visits. JAMA Netw Open. 2021;4(1):e2033967. doi:10.1001/jamanetworkopen.2020.33967

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-09-14 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-05-20 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #JAMA#点击进入话题查看更多相关文章 或评论时插入话题加入讨论

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-01-17 12346c4dm64暂无昵称

    远程,有利有弊

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-01-16 1348580254

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-01-15 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1728777, encodeId=23931e28777dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 14 13:22:44 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734289, encodeId=cf6a1e34289d6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 20 13:22:44 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961901, encodeId=93a496190143, content=<a href='/topic/show?id=08af1024310' target=_blank style='color:#2F92EE;'>#JAMA#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10243, encryptionId=08af1024310, topicName=JAMA)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:28:06 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917328, encodeId=63b391e32824, content=远程,有利有弊, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sun Jan 17 08:55:53 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917278, encodeId=020991e278ee, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe3066532, createdName=1348580254, createdTime=Sat Jan 16 23:10:01 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036392, encodeId=1a181036392e6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jan 15 23:22:44 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917002, encodeId=98fa91e00276, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Jan 15 21:32:43 CST 2021, time=2021-01-15, status=1, ipAttribution=)]
    2021-01-15 wxl882001

    了解

    0

相关资讯

中国首部基本医疗法即将出台:拟医务人员应定期下基层及边远地区工作

8月22日,《中华人民共和国基本医疗卫生与健康促进法(草案)》(下称《草案》)提请十三届全国人大常委会第十二次会议第三次审议。

FDA建数字健康卓越中心,远程医疗和可穿戴设备将能快速审批上市?

昨日美国食品药品监督管理局(FDA)推出了“数字健康卓越中心”( Digital Health Center of Excellence,DHCoE), 进一步推进该机构对数字

HIMSS首席技术官:远程医疗将成主流 患者需要尽快适应

HIMSS首席技术官:远程医疗将成主流 患者需要尽快适应2019年9月16-18日,为期三天的全球医疗信息界最具影响力盛会Health 2.0如期举行,与会专家,学者及各新兴高科技企业畅所欲言,为医疗健康建言献策。HIMSS首席技术和创新官史蒂夫·怀特灵(Steve Wretling)接受采访中,就数字医疗、创新之路、价值医疗等主题发表了自己的看法。采访内容整理如下:wretling_1.pngQ

结束草莽时代的互联网医疗,又迎来医保这阵春风了吗?

2006年,放弃博士学位的李天天在两位友人的邀请下来到杭州,作为一个地道的东北人,李天天在西子湖畔安了家,随他一起搬到杭州的还有他行李里打包的两台丁香园的服务器。

5G远程医疗下的“智慧”防控——没有“硝烟”的疫情阻击战

武汉火神山医院4日上午正式迎来第一批病人,标志该医院正式启用。1月31日,华为联手中国电信,完成了武汉火神山医院首个“远程会诊平台”的网络铺设和设备调试。这套“远程医疗系统”采用华为捐赠的一体化高清视频会议终端TE20视频会议设备和管理平台,并支持1080P高清画质,为远程医疗的顺利实现“保驾护航”。此次远程会诊平台利用的是千兆有线光缆,但配备了5G网络备份。此前,湖北移动、湖北联通已开通蔡甸火神

只有10%患者用过!老百姓其实没那么认可远程医疗

科技进步促进医疗卫生的发展,远程医疗逐渐进入了大众视野。随着越来越多的医院和医疗服务系统开始推行远程医疗,君迪咨询(J.D. Power)的一项针对消费者们的最新研究表明:想要提高大众对远程医疗的接受程度,需要提升消费者对远程医疗的认知、精简项目注册流程、减少会诊排队时间。这份远程医疗满意度研究基于四个因素来衡量健康消费者对其远程医疗服务体验的满意度,分别是:客户服务(45%),咨询(28%),注